Skip to main content
SpringerLink
Log in

Magen/Darm- und Lebererkrankungen

  • Chapter
  • First Online:
Arzneiverordnungs-Report 2022

  • 1930 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Arzneimittelkommission der deutschen Ärzteschaft (2009) Arzneiverordnungen. Empfehlungen zur rationalen Pharmakotherapie, 22. Aufl. Medizinische Medien Informations GmbH, Neu-Isenburg, S 823–835

    Google Scholar 

  • Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362:1071–1081

    CAS  PubMed  Google Scholar 

  • Beyer G, Hoffmeister A, Michl P, Gress TM, Huber W, Algül H, Neesse A, Meining A, Seufferlein TW, Rosendahl J, Kahl S, Keller J, Werner J, Friess H, Bufler P, Löhr MJ, Schneider A, Lynen Jansen P, Esposito I, Grenacher L, Mössner J, Lerch MM, Mayerle J (2022) Collaborators:. S3-Leitlinie Pankreatitis – Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – September 2021 – AWMF Registernummer 021-003. Z Gastroenterol 60(3):419–521. https://doi.org/10.1055/a-1735-3864 (German)

    Article  PubMed  Google Scholar 

  • Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520–1528

    CAS  PubMed  Google Scholar 

  • Bour B, Staub JL, Chousterman M, Labayle D, Nalet B, Nouel O, Pariente A, Tocque E, Bonnot-Marlier S (2005) Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther 21:805–812

    CAS  PubMed  Google Scholar 

  • Bouras EP, Scolapio JS (2004) Gastric motility disorders: management that optimizes nutritional status. J Clin Gastroenterol 38:549–557

    PubMed  Google Scholar 

  • Bundesinstitut für Arzneimittel und Medizinprodukte (2014) Metoclopramidhaltige Arzneimittel: Umsetzung des Durchführungsbeschlusses der EU-Kommission. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RV_STP/m-r/metoclopramid.html

  • Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347:2104–2110

    CAS  PubMed  Google Scholar 

  • Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ (2005) Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352:238–244

    CAS  PubMed  Google Scholar 

  • Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J (2014) Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 370:2387–2396

    PubMed  Google Scholar 

  • Corley DA, Kubo A, Zhao W, Quesenberry C (2010) Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterol 139:93–101

    Google Scholar 

  • Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R (2018) A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med 378:2171–2181

    CAS  PubMed  Google Scholar 

  • Depta JP, Bhatt DL (2012) Antiplatelet therapy and proton pump inhibition: cause for concern? Curr Opin Cardiol 27:642–650

    PubMed  Google Scholar 

  • Deutsche Apothekerzeitung (2018) Bayer knickt ein – Iberogast-Packungsbeilage wird geändert. https://www.deutsche-apotheker-zeitung.de/news/artikel/2018/09/12/bayer-knickt-ein-iberogast-packungsbeilage-wird-geaendert

  • Ehrhardt S, Guo N, Hinz R, Schoppen S, May J, Reiser M, Schroeder MP, Schmiedel S, Keuchel M, Reisinger EC, Langeheinecke A, de Weerth A, Schuchmann M, Schaberg T, Ligges S, Eveslage M, Hagen RM, Burchard GD, Lohse AW (2016) Saccharomyces boulardii to prevent antibiotic-associated diarrhea: a randomized, double-masked, placebo-controlled trial. Open Forum Infect Dis 3:ofw11

    Google Scholar 

  • Emmanuel AV, Kamm MA, Roy AJ, Kerstens R, Vandeplassche L (2012) Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction – a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther 35:48–55

    CAS  PubMed  Google Scholar 

  • European Association for the Study of the Liver (2017) Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67:370–398

    Google Scholar 

  • European Association for the Study of the Liver (2018) EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69:461–511

    Google Scholar 

  • Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, Chen N, Yang M, Skup M, Mulani P, Chao J (2014) Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterol 146:110–118

    CAS  Google Scholar 

  • Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P, UNITI-IM-UNITI Study Group (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375:1946–1960

    CAS  PubMed  Google Scholar 

  • Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L (2021) Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 397:2372–2384

    CAS  PubMed  Google Scholar 

  • Fischbach W, Bornschein J, Hoffmann JC, Koletzko S, Link A, Macke L, Malfertheiner P, Schütte K, Selgrad DM, Suerbaum S, Schulz Ch (2022) Aktualisierte S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) Juli 2022 – AWMF-Registernummer: 021 – 001

    Google Scholar 

  • Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Quigley EM, Task Force on the Management of Functional Bowel Disorders (2014) American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 109(Suppl 1):2–26

    Google Scholar 

  • Gemeinsamer Bundesausschuss (2021) Richtlinie über die Verordnung von Arzneimitteln in der vertragsärztlichen Versorgung in der Version vom 16.09.2021. https://www.g-ba.de/downloads/62-492-2616/AM-RL-2021-08-19_iK-2021-09-16_AT-15-09-2021-B1.pdf

  • Gerbes AL, Labenz J, Appenrodt B, Dollinger M, Gundling F, Gülberg V, Holstege A, Lynen-Jansen P, Steib CJ, Trebicka J, Wiest R, Zipprich A (2019) Aktualisierung der S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“. Z Gastroenterol 57:611–680

    PubMed  Google Scholar 

  • Hagel S, Epple H-J, Feurle GE, Kern WV, Lynen Jansen P, Malfertheinter P, Marth T, Meyer E, Mielke M, Moos V, von Müller L, Nattermann J, Nothacker M, Pox C, Reisinger E, Salzberger B, Salzer HJ, Weber M, Weinke T, Suerbaum S, Lohse AW, Stallmach A (2015) S2k-Leitlinie Gastrointestinale Infektionen und Morbus Whipple. Z Gastroenterol 53:418–459

    CAS  PubMed  Google Scholar 

  • Halm U, Löser C, Löhr M, Katschinski M, Mössner J (1999) A double-blind, randomized, multicentre, crossover study to prove equivalence of pancreatin minimicrospheres versus microspheres in exocrine pancreatic insufficiency. Aliment Pharmacol Ther 13:951–957

    CAS  PubMed  Google Scholar 

  • Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH (2004) Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127:723–729

    CAS  PubMed  Google Scholar 

  • Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield GM, Parés A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Lammers WJ, Hansen BE, van der Meer AJ (2019) Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol 71:357–365

    CAS  PubMed  Google Scholar 

  • Hellers G, Cortot A, Jewell D, Leijonmarck CE, Löfberg R, Malchow H, Nilsson LG, Pallone F, Pena S, Persson T, Prantera C, Rutgeerts P (1999) Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease. Gastroenterology 116:294–300

    CAS  PubMed  Google Scholar 

  • Kark W, Krebs-Richter H, Hotz J (1995) Improving the effect of orthograde colonic lavage with golytely solution by adding dimethicone. Z Gastroenterol 33:20–23

    CAS  PubMed  Google Scholar 

  • Kimer N, Krag A, Møller S, Bendtsen F, Gluud LL (2014) Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 40:123–132

    CAS  PubMed  Google Scholar 

  • Koop H (2018) Verordnungspraxis und Risiken von Protonenpumpenblockern – Fiktion und Fakten? Z Gastroenterol 56:264–274

    PubMed  Google Scholar 

  • Koop H, Fuchs KH, Labenz J, Lynen Jansen P, Messmann H, Miehlke S, Schepp W, Wenzl TG, Mitarbeiter der Leitliniengruppe (2014) Gastroösophageale Refluxkrankheit unter Federführung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) AWMF Register Nr. 021-013. Z Gastroenterol 52:1299–1346

    PubMed  Google Scholar 

  • Krag M, Marker S, Perner A, Wetterslev J, Wise MP, Schefold JC, Keus F, Guttormsen AB, Bendel S, Borthwick M, Lange T, Rasmussen BS, Siegemund M, Bundgaard H, Elkmann T, Jensen JV, Nielsen RD, Liboriussen L, Bestle MH, Elkjær JM, Palmqvist DF, Bäcklund M, Laake JH, Bådstøløkken PM, Grönlund J, Breum O, Walli A, Winding R, Iversen S, Jarnvig IL, White JO, Brand B, Madsen MB, Quist L, Thornberg KJ, Møller A, Wiis J, Granholm A, Anthon CT, Meyhoff TS, Hjortrup PB, Aagaard SR, Andreasen JB, Sørensen CA, Haure P, Hauge J, Hollinger A, Scheuzger J, Tuchscherer D, Vuilliomenet T, Takala J, Jakob SM, Vang ML, Pælestik KB, Andersen KLD, van der Horst ICC, Dieperink W, Fjølner J, Kjer CKW, Sølling C, Sølling CG, Karttunen J, Morgan MPG, Sjøbø B, Engstrøm J, Agerholm-Larsen B, Møller MH, SUP-ICU trial group (2018) Pantoprazole in patients at risk for gastrointestinal bleeding in the ICU. N Engl J Med 379:2199–2208

    CAS  PubMed  Google Scholar 

  • Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schutze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Naucler E, Adler J, Eklund S (2005) Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 22:803–811

    CAS  PubMed  Google Scholar 

  • Lam JR, Schneider JL, Zhao W, Corley DA (2013) Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310:2435–1542

    CAS  PubMed  Google Scholar 

  • Layer P, Andresen V, Allescher H, Bischoff SC, Claßen M, Elsenbruch S, Freitag M, Frieling T, Gebhard M, Goebel-Stengel M, Häuser W, Holtmann G, Keller J, Kreis ME, Kruis W, Langhorst J, Jansen PL, Madisch A, Mönnikes H, Müller-Lissner S, Niesler B, Pehl C, Pohl D, Raithel M, Röhrig-Herzog G, Schemann M, Schmiedel S, Schwille-Kiuntke J, Storr M, Preiß JC; Collaborators:, Andus T, Buderus S, Ehlert U, Engel M, Enninger A, Fischbach W, Gillessen A, Gschossmann J, Gundling F, Haag S, Helwig U, Hollerbach S, Karaus M, Katschinski M, Krammer H, Kuhlbusch-Zicklam R, Matthes H, Menge D, Miehlke S, Posovszky MC, Schaefert R, Schmidt-Choudhury A, Schwandner O, Schweinlin A, Seidl H, Stengel A, Tesarz J, van der Voort I, Voderholzer W, von Boyen G, von Schönfeld J, Wedel T (2021) – AWMF-Registriernummer: 021/016.

    Google Scholar 

  • Lee-Robichaud H, Thomas K, Morgan J, Nelson RL (2010) Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007570.pub2

    Article  PubMed  Google Scholar 

  • Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56:772–781

    CAS  PubMed  Google Scholar 

  • Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ, European Helicobacter Study Group (2012) Management of Helicobacter pylori infection – the Maastricht IV/ florence consensus report. Gut 61:646–664

    CAS  PubMed  Google Scholar 

  • Malfertheiner P, Kandulski A, Venerito M (2017) Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol 14:697–710

    CAS  PubMed  Google Scholar 

  • McFarland LV, Go S (2019) Are probiotics and prebiotics effective in the prevention of travellers’ diarrhea: a systematic review and meta-analysis. Travel Med Infect Dis 27:11–19

    PubMed  Google Scholar 

  • Metcalf TJ, Irons TG, Sher LD, Young PC (1994) Simethicone in the treatment of infant colic: a randomized placebo-controlled multicenter trial. Pediatr Electron Pages 94:29–34

    CAS  Google Scholar 

  • Mössner J (2016) Indikationen, Nutzen und Risiken von Protonenpumpeninhibitoren. Eine Bestandsaufnahme nach 25 Jahren. Dtsch Ärzteblatt 113:477–483

    Google Scholar 

  • National Institute for Health and Care Excellence (2014) Dyspepsia and gastro-oesophageal reflux disease. Investigation and management of dyspepsia, symptoms suggestive of gastro-oesophageal reflux disease, or both. NICE clinical guideline 184 (guidance.nice.org.uk/cg184)

    Google Scholar 

  • Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D, POISE Study Group (2016) A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 375:631–643

    CAS  PubMed  Google Scholar 

  • Niklasson A, Lindström L, Simrén M, Lindberg G, Björnsson E (2010) Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 105:1531–1537

    CAS  PubMed  Google Scholar 

  • Pantano F, Mannocchi G, Marinelli E, Gentili S, Graziano S, Busardò FP, di Luca NM (2017) Hepatotoxicity induced by greater celandine (Chelidonium majus L.): a review of the literature. Eur Rev Med Pharmacol Sci 21(1 Suppl):46–52

    CAS  PubMed  Google Scholar 

  • Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P (2017) Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011194.pub3

    Article  PubMed  PubMed Central  Google Scholar 

  • Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007) Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45:549–559

    PubMed  Google Scholar 

  • Reimer C, Søndergaard B, Hilsted L, Bytzer P (2009) Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 137:80–87

    CAS  PubMed  Google Scholar 

  • Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S (2010) Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 138:1286–1296

    CAS  PubMed  Google Scholar 

  • Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J, OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376:1723–1736

    CAS  PubMed  Google Scholar 

  • Sandborn WJ, Feagan BG, D’Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S, True North Study Group (2021) Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med 385(14):1280–1291. https://doi.org/10.1056/NEJMoa2033617

    Article  CAS  PubMed  Google Scholar 

  • Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C, Group US (2019a) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381:1201–1214

    CAS  PubMed  Google Scholar 

  • Sands BE, Peyrin-Biroulet L, Loftus EV Jr., Danese S, Colombel JF, Toruner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S, Group VS (2019b) Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 381:1215–1226

    CAS  PubMed  Google Scholar 

  • Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E (2018) Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol 11:1123–1134

    CAS  PubMed  Google Scholar 

  • Savoldi A, Carrara E, Grahm DY, Conti M, Tacconelli E (2018) Prevalence of antibiotic resistance in helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology 155:1372–1382

    PubMed  Google Scholar 

  • Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, Holland L, Wilson K, Bhala N, Hawkey C, Hochberg M, Hunt R, Laine L, Lanas A, Patrono C, Baigent C (2018) Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomized trials. Lancet Gastroenterol Hepatol 3:231–241

    PubMed  PubMed Central  Google Scholar 

  • Schmieder G, Stankov G, Zerle G, Schinzel S, Brune K (1993) Observer-blind study with metamizole versus tramadol and butylscopolamine in acute biliary colic pain. Arzneim Forsch 43:1216–1221

    CAS  Google Scholar 

  • Sebode M, Kloppenburg A, Aigner A, Lohse AW, Schramm C, Linder R (2020) Population based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalence based on ICD codes, yet deficits in medical treatment. Z Gastroenterol 58:431–438

    PubMed  Google Scholar 

  • Siegmund E, Löhr JM, Schuff-Werner P (2004) Die diagnostische Validität nichtinvasiver Pankreasfunktionstests – Eine Metaanalyse. Z Gastroenterol 42:1117–1128

    CAS  PubMed  Google Scholar 

  • Sjöstedt S, Befrits R, Sylvan A, Harthon C, Jörgensen L, Carling L, Modin S, Stubberöd A, Toth E, Lind T (2005) Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 22:183–191

    PubMed  Google Scholar 

  • Smith DS, Ferris CD (2003) Current concepts in diabetic gastroparesis. Drugs 63:1339–1358

    PubMed  Google Scholar 

  • Stedman CA, Barclay ML (2000) Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14:963–978

    CAS  PubMed  Google Scholar 

  • Sudduth RH, DeAngelis S, Sherman KE, McNally PR (1995) The effectiveness of simethicone in improving visibility during colonoscopy when given with a sodium phosphate solution: a double-bind randomized study. Gastrointest Endosc 42:413–415

    CAS  PubMed  Google Scholar 

  • Teschke R, Wolff A, Frenzel C, Schulze J, Eickhoff A (2012) Herbal hepatotoxicity: a tabular compilation of reported cases. Liver Int 32:1543–1556

    PubMed  Google Scholar 

  • Tromm A, Bunganič I, Tomsová E, Tulassay Z, Lukáš M, Kykal J, Bátovský M, Fixa B, Gabalec L, Safadi R, Kramm HJ, Altorjay I, Löhr H, Koutroubakis I, Bar-Meir S, Stimac D, Schäffeler E, Glasmacher C, Dilger K, Mohrbacher R, Greinwald R, International Budenofalk Study Group (2011) Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn’s disease. Gastroenterology 140:425–434

    CAS  PubMed  Google Scholar 

  • Ueberschaer H, Allescher HD (2017) Protonenpumpenhemmer – Nebenwirkungen und Komplikationen der langfristigen Protonenpumpenhemmereinnahme. Z Gastroenterol 55:636–674

    Google Scholar 

  • Wei D, Heus P, van de Wetering FT, van Tienhove G, Verleye L, Scholten RJ (2018) Probiotics for the prevention or treatment of chemotherapy or radiotherapy-related diarrhoea in people with cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008831.pub3

    Article  PubMed  PubMed Central  Google Scholar 

  • Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY (2013) Rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy: a meta-analysis. Gastroenterol Res Pract. https://doi.org/10.1155/2013/236963

    Article  PubMed  PubMed Central  Google Scholar 

  • Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z (2019) Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 365:l1580

    PubMed  PubMed Central  Google Scholar 

  • Zimmermann T, Jansen PL, Sarrazin C, Vollmar J, Zeuzem S (2018) S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV)-Infektion“. Z Gastroenterol 56:e53–e115

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum für Innere Medizin I. Medizinische Klinik und Poliklinik (Gastroenterologie mit Sektionen Infektiologie und Tropenmedizin), Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland

    Prof. Dr. med. Ansgar W. Lohse

  2. Zentrum für Innere Medizin I. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20251, Hamburg, Deutschland

    Prof. Dr. med. Samuel Huber

Authors
  1. Prof. Dr. med. Ansgar W. Lohse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Samuel Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ansgar W. Lohse .

Editor information

Editors and Affiliations

  1. Arzneimittelkommission der deutschen Ärzteschaft, Berlin, Deutschland

    Wolf-Dieter Ludwig

  2. Institut für Pharmakologie, Klinikum Bremen-Mitte, Bremen, Deutschland

    Bernd Mühlbauer

  3. Institut für Pharmakologie, Medizinische Hochschule Hannover, Hannover, Deutschland

    Roland Seifert

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lohse, A.W., Huber, S. (2022). Magen/Darm- und Lebererkrankungen. In: Ludwig, WD., Mühlbauer, B., Seifert, R. (eds) Arzneiverordnungs-Report 2022. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-66303-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-66303-5_12

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-66302-8

  • Online ISBN: 978-3-662-66303-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation